tirzepatide discontinuation weight regain after the withdrawal of (Zepbound) may wipe out many of the cardiometabolic gains made during weight loss, a post-hoc analysis of the SURMOUNT-4 trial indicated. Read more at: https://www.medpagetoday.com/endocrinology/obesity Tirzepatide enhances weight loss with

CrossRef Real-world prescription patterns of guideline-recommended therapies in heart failure across China Yingming Zheng, Heng Guo, Wanqing Song, Xiao Luo, Hongge Yang, Zhenning Lu, Xingang Li, Dandan Li Naunyn-Schmiedeberg's Archives of Pharmacology.2026;[Epub] CrossRef Income Persistence and the Risk of Hepatocellular Carcinoma in Individuals with Type 2 Diabetes Jong-Ha Baek, Yong-Moon Mark Park, Benjamin C

Conclusions GLP1-RAs are possible risk factors in intestinal obstruction, including FIBO, and should be recommended to patients with caution

Animal studies show GLP-1 receptor agonists like semaglutide reduce alcohol intake in rodents, but there is no research in humans yet to confirm what's being reported by patients, he says

Cons As with any prescription medication, there are also pros and cons to consider before starting use

Dr Wendy Sweet, PhD & Member: Australasian Society of Lifestyle Medicine/ Womens Healthy Ageing Researcher & MyMT Founder ]

This log helps your physician spot patternsfor example, whether low blood sugar tends to happen at specific times or after certain mealsand make informed decisions about dose adjustments